Date of event
-
Continuing Education Credits
CME
ABIM MOC

UPDATEThe OnDemand 2021 AASLD Emerging Topic Conference was released on May 17, 2021 and is available in AASLD’s educational portal, LiverLearning® until December 31, 2021. Register for / view the OnDemand Course


 

Course Description / Needs Statement

This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population. A review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers will be covered along with an assessment of HBV cure’s impact on HBV epidemiology and population health.

Program Chairs

  • Mindie H. Nguyen, MD, MAS, FAASLD
  • Harry A. Janssen, MD, PhD, FAASLD

Conference Format

The online live-streaming conference will have pre-recorded presentations for viewing along with live elements including panel discussions and the opportunity to get your faculty questions answered in real time with both Chat and Q&A features available throughout the event.

Continuing Education

  • CME Hours: 7.00 AMA PRA Category 1 Credits™
  • MOC Points: 7.00 ABIM MOC Points

 

OnDemand Product Pricing:

  • Member — $175 
  • Trainee & Assoc. Members — $100 
  • Student Member — $50 
  • Non-Member — $225 
    Any physician, scientist, or researcher with doctoral-level training who is not employed by Industry (pharma/device/etc.)
  • Trainee & Assoc. Non-Member — $150 
    Any physician, scientist or researcher in a training program as certified by the director of their training program. This category also includes, but is not limited to, the degrees of MS, NP, PA, RN, and other related or comparable degrees.
  • Student Non-Member — $75 
  • Industry — $450 
    Any Industry (pharma/device/etc.) employee with or without medical training.
  • Patient / Patient Advocate — Free

Session I: Population
Moderators: Brian J. McMahon, MD, FAASLD and John W. Ward, MD

  • 10:00 am – 10:05 am ET
    Welcome and Opening Remarks
    Harry L.A. Janssen, MD, PhD
  • 10:05 am – 10:08 am ET
    Moderator Opening Remarks
  • 10:08 am – 10:29 am ET
    HBV - Global Epidemiology, Current Demographics/Comorbidities, HCC Surveillance, and Connection to Care
    Mindie H. Nguyen, MD, MAS, FAASLD
  • 10:29 am – 10:52 am ET
    Can We Improve HBV Screening and Monitoring with POC and New Diagnostics - Implications in High and Resource Limited Countries?
    Jordan J. Feld, MD, MPH, FAASLD
  • 10:52 am – 11:09 am ET
    Panel Discussion
  • 11:09 am – 11:20 am ET
    Break

Session II: Current Treatment
Moderators: Robert S. Brown, Jr., MD, MPH, FAASLD and George V. Papatheodoridis, MD, PhD, FAASLD

  • 11:20 am – 11:23 am ET
    Moderator Opening Remarks
  • 11:23 am – 11:46 am ET
    Current Therapeutic Strategies and Standard Management Guidance
    Ira M. Jacobson, MD, FAASLD
  • 11:46 am – 12:01 pm ET
    How Do We Define Elevated ALT and Viral Load and Should We Treat Those with Minimal Elevation?
    Douglas T. Dieterich, MD, FAASLD and Norah Terrault, MD, MPH, FAASLD
  • 12:01 pm – 12:17 pm ET
    Can We Stop Nucleos(t)ides: Who and When?
    Yao-Chun Hsu, MD, MSc, PhD and Paul Martin, MD, FAASLD
  • 12:17 pm – 12:47 pm ET
    Panel Discussion
  • 12:47 pm – 12:50 pm ET
    Closing Remarks
    Mindie H. Nguyen, MD, MAS, FAASLD

Session III: HBV Cure
Moderators: Raymond T. Chung, MD, FAASLD and Seng Gee Lim, MD, MBBS, FAASLD

  • 10:00 am – 10:08 am ET
    Welcome and Opening Remarks
    Raymond T. Chung, MD, FAASLD and Seng Gee Lim, MD, MBBS, FAASLD
  • 10:08 am – 10:28 am ET
    How Do We Define HBV Cure?
    Marc G. Ghany, MD, MHSc, FAASLD
  • 10:28 am – 10:49 am ET
    HBV RNA and HBCrAg as Marker for cccDNA and Transcription
    Thomas Berg, MD, FAASLD
  • 10:49 am – 11:09 am ET
    Immunologic Biomarkers in and Outside the Liver
    Georg M. Lauer, MD, PhD
  • 11:09 am – 11:29 am ET
    Inhibitors of HBV Entry and Release
    Heiner Wedemeyer, MD
  • 11:29 am – 11:44 am ET
    Break
  • 11:44 am – 12:01 pm ET
    Capsid Inhibition by Assembly Modulation
    Man-Fung Yuen, MD, PhD, DSc
  • 12:01 pm – 12:21 pm ET
    RNA Interference: si-RNA and Antisense Oligonucleotides
    Edward J. Gane, MD
  • 12:21 pm – 12:45 pm ET
    New Compounds for Hepatitis Delta: Finite or Indefinte Therapy?
    Robert G. Gish, MD, FAASLD
  • 12:45 pm – 1:10 pm ET
    Panel Discussion
  • 1:10 pm – 1:15 pm ET
    Closing Remarks
    Raymond T. Chung, MD, FAASLD and Seng Gee Lim, MD, MBBS, FAASLD

Session IV: From HBV Cure to Population
Moderators: Paul Kwo, MD, FAASLD and Mala Maini, MD, PhD

  • 10:00 am – 10:05 am ET
    Welcome and Opening Remarks
    Harry L.A. Janssen, MD, PhD, FAASLD
  • 10:05 am – 10:08 am ET
    Moderator Opening Remarks
  • 10:08 am – 10:23 am ET
    How to Restore Innate Immunity: TLR Agonists, RIG-I Agonists, STING
    Kyong-Mi Chang, MD, FAASLD
  • 10:23 am – 10:43 am ET
    How to Restore Adaptive Immunity: Therapeutic Vaccination, Checkpoint Inhibition
    Barbara Rehermann, MD, FAASLD
  • 10:43 am – 11:08 am ET
    How to Distinguish Antiviral, Pathogenic and DILI Flares
    Robert J. Fontana, MD, FAASLD
  • 11:08 am – 11:28 am ET
    Break
  • 11:28 am – 11:48 am ET
    How to Combine New Agents and Navigate Efficacy and Toxicity
    Harry L. A. Janssen, MD, PhD, FAASLD
  • 11:48 am – 12:00 pm ET
    Impact of HBV Cure on Epidemiology and Care Cascade
    Anna S. Lok, MD, FAASLD
  • 12:00 pm – 12:30 pm ET
    Panel Discussion
  • 12:30 pm – 12:35 pm ET
    Closing Remarks
    Mindie H. Nguyen, MD, MAS, FAASLD

Needs Statement

This conference will provide a comprehensive and in-depth discussion of the most updated treatment strategies as well as data/care gap to prevent and manage the HBV population, a review of the preclinical and clinical frontiers of HBV cure molecules after a state-of-the-art review of novel molecular and immunologic HBV cure markers, and an assessment of HBV cure’s impact on HBV epidemiology and population health.

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Identify populations to screen for HBV, to vaccinate, and to treat with focus on groups with controversial treatment indications.
  • Interpret results of new molecular and immunologic HBV cure biomarkers and learn about most updated HBV cure therapeutic development.
  • Detect areas of data gaps for future epidemiological, clinical, and translational research.

Target Audience

  • Hepatologists
  • Gastroenterologists
  • Nurses
  • Nurse Practitioners
  • Pharmacists
  • Physician Assistants
  • Transplant Coordinators
  • Surgeons
  • Fellows/Trainees
  • Infectious Disease Specialists
  • Public Health Workers/Stake Holders
  • Epidemiologists
  • Virologists
  • Immunologists
  • Industry Stakeholders

This activity was planned in the context of the following ACGME/IOM/IPEC competencies:

  • Patient Care and Procedural Skills
  • Medical Knowledge
  • Practice-based Learning and Improvement
  • Interpersonal and Communication Skills
  • Professionalism
  • Systems-based Practice
  • Provide Patient-centered Care
  • Work in Interdisciplinary Teams
  • Employ Evidence-based Practice
  • Apply Quality Improvement
  • Utilize Informatics
  • Values/Ethics for Interprofessional Practice
  • Roles/Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

Credits Offered

  • Continuing Medical Education (CME): 7.00 AMA PRA Category 1 Credits™
  • Maintenance of Certification (MOC): 7.00 ABIM MOC Points

Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Claiming CME Credits and ABIM MOC Points

CME Credits
Physicians and other health care professionals seeking AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Thursday, April 15, 2021. The CME evaluation will be available to you upon completion of the on-demand course.

MOC Points
Physicians seeking ABIM MOC points must complete the electronic CME and MOC evaluation by Thursday, April 15, 2021. Requests for MOC after this date will not be honored. The MOC evaluation is included in the CME evaluation.

MOC Points will be reported to the ABIM by the end of April 2021 for attendees who successfully complete the MOC evaluation.